ABCAM PLC Notice of Results (2947W)

TIDMABC

RNS Number : 2947W

ABCAM PLC

17 August 2022

ABCAM PLC

Abcam to Report Half Year Results on Monday, September 12 , 202 2

17 August 2022, Cambridge, UK - Abcam plc (Nasdaq: ABCM ; AIM: ABC) (" Abcam " or the " Company "), a global leader in the supply of life science research tools, will report its results for the 6-month period ended 3 0 June 202 2 at 12 .00 p .m. BST ( 7 .00 a.m. E D T) on 12 September 2022 .

Following the announcement, the Company will host a live teleconference and webcast at 13 :00 p.m. BST ( 8 :00 a.m. E D T) that same day (details below).

To access the webcast, please use the following link:

https://events.q4inc.com/earnings/LONABC/AbcamplcH12022

The press release and the live audio webcast will also be available in the investor section of Abcam's corporate website at corporate.abcam.com/investors/reports-presentations/ . An archive will be available after the call at that same address.

For further information please contact:

 
Abcam                                                   [phone] 
Tommy Thomas, CPA, Vice President, Investor Relations 
Numis - Nominated Advisor & Joint Corporate Broker      + 44 (0) 20 7260 1000 
Freddie Barnfield / Duncan Monteith 
Morgan Stanley - Joint Corporate Broker                 + 44 (0) 207 425 8000 
Tom Perry / Luka Kezic 
FTI Consulting                                          + 44 (0) 20 3727 1000 
Ben Atwell / Julia Bradshaw 
 

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

   For more information, please visit  www.abcam.com   or  www.abcamplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORGLGDILGBDGDR

(END) Dow Jones Newswires

August 17, 2022 03:30 ET (07:30 GMT)